Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS)
- PMID: 20141389
- PMCID: PMC2847847
- DOI: 10.3109/00952990903490758
Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS)
Abstract
Background: Patients' substance use problems are a particularly understudied aspect of psychosocial variables in cancer treatment.
Objectives: The specific hypothesis tested was that lifetime substance use disorders increased the risk of adverse outcome, in the context of other psychosocial and clinical characteristics demonstrated in other studies to have an impact on treatment outcome.
Method: Prospective cohort study of 106 adults with chronic myelogenous leukemia or primary myelodysplastic syndrome. None satisfied criteria for current substance abuse or dependence, but the lifetime rates of substance use disorders in this sample were 28% for alcohol, 12% for cannabis, and 9% for cocaine.
Results: Participants received treatment as directed by their physicians, and were followed until death or the end of the study (median 1.5 years). Twenty-eight died. Multivariate survival analysis identified three predictors of outcome: lifetime cocaine use, associated with a six-fold increased risk of death (p = .04), and two protective variables, baseline hemoglobin (p = .002) and estimated intelligence quotient (IQ) (p = .04).
Conclusion: The results of this study highlight the potential significance of substance use disorders, and lifetime cocaine diagnoses in particular, on treatment outcome for people with chronic myelogenous leukemia or myelodysplastic syndrome. Whereas neither lifetime alcohol nor cannabis use were associated with survival on either the univariate or multivariate models of survival, lifetime cocaine diagnoses were associated with significant six-fold increased risk of death (p = .04).
Conflict of interest statement
The authors report no conflicts of interest. They alone are responsible for the content and writing of the article.
Figures
Similar articles
-
Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome.Arch Clin Neuropsychol. 2013 Jun;28(4):363-74. doi: 10.1093/arclin/acs141. Epub 2013 Feb 7. Arch Clin Neuropsychol. 2013. PMID: 23391504 Free PMC article.
-
Prognostic significance of monocytosis in patients with myeloproliferative disorders.Leuk Lymphoma. 2006 Mar;47(3):417-23. doi: 10.1080/10428190500305448. Leuk Lymphoma. 2006. PMID: 16396764
-
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1. Biol Blood Marrow Transplant. 2016. PMID: 27377901 Free PMC article.
-
Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.Leukemia. 1997 Feb;11(2):206-11. doi: 10.1038/sj.leu.2400558. Leukemia. 1997. PMID: 9009082 Review.
-
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.Hematology. 2018 Dec;23(10):778-784. doi: 10.1080/10245332.2018.1471794. Epub 2018 May 14. Hematology. 2018. PMID: 29757120 Review.
Cited by
-
Expert consensus-based guidance on approaches to opioid management in individuals with advanced cancer-related pain and nonmedical stimulant use.Cancer. 2023 Dec 15;129(24):3978-3986. doi: 10.1002/cncr.34921. Epub 2023 Sep 11. Cancer. 2023. PMID: 37691479 Free PMC article.
-
The impact of substance use on health care utilization, treatment, and outcomes in patients with non-small cell lung cancer.J Thorac Dis. 2022 Oct;14(10):3865-3875. doi: 10.21037/jtd-21-1992. J Thorac Dis. 2022. PMID: 36389291 Free PMC article.
-
Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer.Gynecol Oncol Rep. 2019 Mar 27;28:116-119. doi: 10.1016/j.gore.2019.03.016. eCollection 2019 May. Gynecol Oncol Rep. 2019. PMID: 31011609 Free PMC article.
-
Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome.Arch Clin Neuropsychol. 2013 Jun;28(4):363-74. doi: 10.1093/arclin/acs141. Epub 2013 Feb 7. Arch Clin Neuropsychol. 2013. PMID: 23391504 Free PMC article.
-
Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review.Subst Abuse Rehabil. 2016 Jun 2;7:71-9. doi: 10.2147/SAR.S85409. eCollection 2016. Subst Abuse Rehabil. 2016. PMID: 27330340 Free PMC article. Review.
References
-
- Passik SD, Portenoy RK, Ricketts PL. Substance abuse issues in cancer patients. Part 1: Prevalence and diagnosis. Oncology (Williston Park) 1998;12:517–521. - PubMed
-
- Stagno SJ, Busby K, Shapiro A, Kotz MM. Patients at risk: Addressing addiction in patients undergoing hematopoetic SCT. Bone Marrow Transplant. 2008;42:221–226. - PubMed
-
- Hoodin F, Uberti JP, Lynch TJ, Steele P, Ratanatharathorn V. Do negative or positive emotions differentially impact mortality after adult stem cell transplant? Bone Marrow Transplant. 2006;38:255–264. - PubMed
-
- Polednak AP. Documentation of alcohol use in hospital records of newly diagnosed cancer patients: A population based study. Am J Drug Alcohol Abuse. 2007;33:403–409. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous